Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes.

OBJECT World Health Organization (WHO) Grade I (benign) meningiomas with atypical features may behave more aggressively than similarly graded tumors without atypical features. Here, the prognostic significance of atypical features in benign meningiomas was determined. METHODS Data from patients diagnosed with WHO Grade I benign meningiomas per the 2007 WHO criteria and who underwent surgery between 2002 and 2012 were retrospectively reviewed. Patients were stratified by the absence or presence of 1 to 2 atypical features with review of the clinical and histological factors. RESULTS A total of 148 patients met the inclusion criteria (n = 77 with atypia; n = 71 without atypia). The median follow-up duration after pathological diagnosis was 37.5 months. Thirty patients had progression/recurrence (P/R) after initial treatment, and 22 (73%) of 30 patients with P/R had 1-2 atypical features. The presence of atypical features was significantly associated with P/R (p = 0.03) and independent of the MIB-1 labeling index. The 1-year and 5-year actuarial rates of P/R were 9.6% versus 1.4% and 30.8% versus 13.8% fortumors with and without atypical features, respectively. Higher Simpson grade resection (II-IV vs I) was associated with the increased risk of P/R (p < 0.001). Stratification of patients into low-risk (Simpson Grade I), intermediate-risk (Simpson Grade II-IV with no atypical features), and high-risk groups (Simpson Grade II-IV with atypical features) was significantly correlated with increased risk of P/R (p < 0.001). CONCLUSIONS Patients with benign meningiomas with atypical features and those undergoing Simpson Grade II-IV resection are at significantly increased risk of P/R. Patients with these features may benefit from the consideration of additional surgery and/or radiation therapy.

[1]  C. López-Ginés,et al.  Genetic changes with prognostic value in histologically benign meningiomas. , 2013, Clinical neuropathology.

[2]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[3]  K. Kawai,et al.  Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas. , 2012, Journal of neurosurgery.

[4]  A. von Deimling,et al.  Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. , 2011, International journal of radiation oncology, biology, physics.

[5]  J. Villano,et al.  Update on meningiomas. , 2011, The oncologist.

[6]  M. Berger,et al.  The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. , 2010, Journal of neurosurgery.

[7]  Pascal Pommier,et al.  Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. , 2009, International journal of radiation oncology, biology, physics.

[8]  G. Barnett,et al.  Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. , 2009, International journal of radiation oncology, biology, physics.

[9]  W. Curry,et al.  LONG‐TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION , 2009, Neurosurgery.

[10]  A. Perry,et al.  Gray Zones in Brain Tumor Classification: Evolving Concepts , 2008, Advances in anatomic pathology.

[11]  B. Guthrie,et al.  Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. , 2008, Neurosurgical focus.

[12]  D. Kong,et al.  Relationship between malignant subtypes of meningioma and clinical outcome , 2007, Journal of Clinical Neuroscience.

[13]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[14]  J. Schramm,et al.  Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  P. Gutin,et al.  Diagnosis and Treatment of Atypical and Anaplastic Meningiomas: A Review , 2005, Neurosurgery.

[16]  I. Whittle,et al.  The accuracy of meningioma grading: a 10‐year retrospective audit , 2005, Neuropathology and applied neurobiology.

[17]  M. Maor,et al.  Radiotherapy after surgery for benign cerebral meningioma. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  Chih‐Yi Hsu,et al.  Histopathology and MIB‐1 labeling index predicted recurrence of meningiomas , 2002, Cancer.

[19]  R. Ojemann,et al.  Management of Atypical and Malignant Meningiomas: Role of High-dose, 3D-conformal Radiation Therapy , 2000, Journal of Neuro-Oncology.

[20]  J M Buatti,et al.  Benign meningiomas: primary treatment selection affects survival. , 1997, International journal of radiation oncology, biology, physics.

[21]  L. Palma,et al.  Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. , 1997, Journal of neurosurgery.

[22]  M. Fukui,et al.  MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management , 1994, Cancer.

[23]  B J Goldsmith,et al.  Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. , 1994, Journal of neurosurgery.

[24]  W. Friedman,et al.  The meningioma controversy: postoperative radiation therapy. , 1988, International journal of radiation oncology, biology, physics.

[25]  J. Jääskeläinen,et al.  Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. , 1986, Surgical neurology.

[26]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[27]  Thomas Backer-Grøndahl,et al.  The histopathological spectrum of human meningiomas. , 2012, International journal of clinical and experimental pathology.

[28]  E. B. Butler,et al.  Malignant meningioma: An indication for initial aggressive surgery and adjuvant radiotherapy , 2004, Journal of Neuro-Oncology.

[29]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[30]  E. Wenkel,et al.  Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[31]  G. Barnett,et al.  Local control and overall survival in atypical meningioma: a retrospective study. , 2000, International journal of radiation oncology, biology, physics.

[32]  A. Asai,et al.  Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas , 1996, Acta Neuropathologica.